APL-130277 is the Company’s fast-acting, sublingual, thin filmstrip formulation of apomorphine. OFF episodes are a complication of Parkinson’s disease that leave patients rigid and unable to move and
Both the diabetes and CV standards were established in an effort to make clinical research more efficient while continuing to support the scientific nature of the research. The
Created by Atlas Venture and Caribou Biosciences, together with leading scientists who have pioneered and shaped the field of CRISPR biology, Intellia leverages exclusive access to one of
The collaboration will focus on new therapeutic approaches for the treatment of various acute neurological conditions resulting from neurovascular instability. This discovery collaboration brings together Edge’s scientific expertise
"We are proud and hopeful to play a role to develop a treatment that could potentially reduce the rate of prosthesis abandonment for those who have so honorably
This invention is for a nanotechnology process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid nanosomes for use in combination therapy by means of Aphios’ SuperFluids technology
This announcement follows the successful testing of DCR-PH1 in combination with Tekmira’s LNP technology in animal models, including mice and non-human primates. Under the agreement, Dicerna will pay
KTE-C19 is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient’s T cells to express a CAR that is designed to target CD19, a protein
Licensing provides RetroSense with worldwide access to key intellectual property which reinforces the Company’s dominant position in optogenetics for vision restoration. The licensed intellectual property is based on
Dr. Gareth Lavery, a prominent researcher with the University of Birmingham’s Centre for Endocrinology, Diabetes and Metabolism (CEDAM), has been awarded a prestigious Senior Fellowship in Basic Biomedical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.